UK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb.
The US firm will use use Summit's proprietary Seglin technology to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Summit will receive a $100,000 technology access fee and is eligible for research, development and regulatory milestones of up to $30m per product, plus royalties on worldwide sales of products arising from the technology.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Eckoh, the provider of speech recognition and associated payment solutions, has been awarded a three year contract with international services company Serco to provide hosted speech recognition services to a client within central government. It is the company's first contract win with Serco, one of the UK's leading outsourcing firms.
JH
-
Why wealthy whisky enthusiasts are leaving BritainCollectables Wealthy whisky enthusiasts are heading to tax-friendly countries such as Dubai, where there is more disposable income to spend on collectable luxuries like rare whisky.
-
Zoopla: Property tax speculation creates uncertainty for a third of home buyersProperty tax rumours could impact homes valued at over £500,000, potentially triggering a housing market slowdown, Zoopla has warned
